FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine and is a method of adjusting the circadian rhythm of cortisol to a 24-hour circadian rhythm and maintaining a 24-hour circadian rhythm. Method comprises orally administering to the patient an effective amount of a tasimelteon once a day before going to bed, preferably 0.5-1.5 hours before the desired time for falling asleep, preferably the dose of tasimelteon is 10-00 mg. Patients may have a disturbed perception of light or be blind. Introduction of tasimelteon can begin on a day, when the acrophase of aMT6s in urine will take place between 5.5 hours to the required awakening time and up to 2.5 hours after the desired awakening time.
EFFECT: implementation of the invention ensures the normalization of the circadian rhythm of cortisol.
8 cl, 17 dwg, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF CIRCADIAN RHYTHM VIOLATIONS | 2013 |
|
RU2631602C2 |
| TREATMENT OF CIRCADIAN RHYTHM DISORDERS | 2013 |
|
RU2748386C2 |
| WAY TO IMPROVE SLEEP | 2020 |
|
RU2804441C2 |
| METABOLITES (1R-TRANS)-N-[[2-(2,3-DIGIDRO-4-BENZOFURANYL)CYCLOPROPYL]-METHYL]PROPANAMIDE | 2013 |
|
RU2632889C2 |
| AGENT FOR TREATMENT OF DESYNCHRONIZATION TROUBLES, AND PHARMACEUTICAL COMPOSITION | 1994 |
|
RU2160101C2 |
| METHOD OF TREATMENT OF PATHOLOGICAL DEVIATIONS AT DIABETES MELLITUS OF TYPE-2 | 1992 |
|
RU2104698C1 |
| MELATONIN AGONIST THERAPY | 2007 |
|
RU2488392C2 |
| DIAGNOSTIC TECHNIQUE FOR CLINICALLY LATENT HYPERCORTICOIDISM IN PATIENTS SUFFERING FROM STYPE 2 DIABETES MELLITUS OR OBESITY | 2012 |
|
RU2521387C1 |
| METHOD FOR NORMALISING INDIVIDUAL'S DIURNAL RHYTHM | 2013 |
|
RU2533965C1 |
| METHOD FOR TREATING AND PREVENTING BENZODIAZEPINE GROUP MEDICAMENT ADDICTION OR INSENSITIVITY OR TOLERATION SYMPTOMS | 1996 |
|
RU2182001C2 |
